Skip to content
MINIMUM Bio drug target discovery company logo
  • Home
  • NEWS
  • Partner With Us
  • Pipeline
  • Our Science
  • Phagent AI
  • Team
  • Contact
  • Home
  • NEWS
  • Partner With Us
  • Pipeline
  • Our Science
  • Phagent AI
  • Team
  • Contact

Tag: Revolution Medicines

The best oncology drug launch in history

Revolution Medicines’ Rasonque earned $198 million in its first five weeks, a strong debut for a non-degrading molecular glue drug.

Rasonque momentum builds as glue degraders advance in immunology

Daraxonrasib (Rasonque) combination data at ESMO 2026, a second Phase 2 for Monte Rosa’s VAV1 glue degrader, and new AI tools for molecular glue research.

MINIMUM Bio drug target discovery company logo

Illuminating the undruggable proteome.

All rights reserved